Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

progression-free survival

  • You have access
    Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403)
    NAOTOSHI SUGIMOTO, JUNJI KAWADA, YOSHIO OKA, SHUGO UEDA, KOHEI MURAKAMI, KAZUHIRO NISHIKAWA, YUKINORI KUROKAWA, KAZUMASA FUJITANI, HISATO KAWAKAMI, SHUNJI ENDO, DAISUKE SAKAI, TOSHIO SHIMOKAWA and TAROH SATOH
    Anticancer Research January 2025, 45 (1) 307-313; DOI: https://doi.org/10.21873/anticanres.17418
  • Open Access
    Preoperative Tumor Growth Rate Does Not Predict Overall or Progression-free Survival in Patients With Glioblastoma
    JAN LEPPERT, CLAUDIA DITZ, JAKOB MATSCHKE, MARIA.VITTORIA MATONE, PATRICK KUPPLER, CHRISTINA HILLBRICHT, HARALD KRENZLIN, NAUREEN KERIC, HANNES SCHACHT, CHRISTIAN ZIEMANN, ELISA MARIA GROH, LARYSA LIUBICH, OKSANA ZEMSKOVA, DIRK RADES and ANASTASSIA LĂ–SER
    Anticancer Research November 2024, 44 (11) 5043-5049; DOI: https://doi.org/10.21873/anticanres.17328
  • You have access
    Awake Surgery for Right Frontal Lobe Glioma: Preserving Emotional Recognition and Facilitating Early Return to Work
    KOSEI YAMAMOTO, RYOTA TAMURA, SOTA WAKAHARA, KAZUHIRO KOJIMA, MAKIKO ANDO, MASAHIRO YO, KENZO KOSUGI, YOHEI KITAMURA, RYO UEDA, AIKO ISHIKAWA, TETSUYA TSUJI and MASAHIRO TODA
    Anticancer Research October 2024, 44 (10) 4609-4615; DOI: https://doi.org/10.21873/anticanres.17291
  • Open Access
    Genetic Alteration of p18INK4C and its Expression in Peripheral Blood Mononuclear Cells Were Not Associated With Progression-free Survival of Multiple Myeloma Patients After Autologous Stem Cell Transplant
    JUNAN LI and MING J. POI
    Anticancer Research September 2024, 44 (9) 3771-3776; DOI: https://doi.org/10.21873/anticanres.17201
  • Open Access
    The Predictive Value of Different Glasgow Prognostic Scores and the LabBM Score for Patients With Recurrent Glioblastoma
    DIRK RADES, OKSANA ZEMSKOVA, JAN LEPPERT and NATHAN Y. YU
    Anticancer Research September 2024, 44 (9) 3973-3981; DOI: https://doi.org/10.21873/anticanres.17226
  • Open Access
    Prognostic Factors for Progression-free Survival and Overall Survival After Recurrence of Glioblastoma
    OKSANA ZEMSKOVA, NATHAN Y. YU, JAN LEPPERT and DIRK RADES
    Anticancer Research July 2024, 44 (7) 3059-3066; DOI: https://doi.org/10.21873/anticanres.17119
  • You have access
    Real Clinical Practice of Combined Atezolizumab Plus Chemotherapy in Patients With Small Cell Lung Cancer
    SATOSHI ANO, NORIHIRO KIKUCHI, SHINICHIRO OKAUCHI, TAKESHI NUMATA, RYOTA NAKAMURA, TOSHIHIRO SHIOZAWA, HIROKO WATANABE, TOMOHIRO TAMURA, KUNIHIKO MIYAZAKI, SHIGEN HAYASHI, TAKAAKI YAMASHITA, KOICHI KURISHIMA, MASAHARU INAGAKI, TAKAYUKI KABURAGI, TAKEO ENDO, HIROAKI SATOH and NOBUYUKI HIZAWA
    Anticancer Research June 2024, 44 (6) 2725-2730; DOI: https://doi.org/10.21873/anticanres.17080
  • You have access
    Results of Definitive (Chemo)radiotherapy Using Computed Tomography-based Brachytherapy for Cervical Cancer
    TOMOMI AOSHIKA, SHIN-EI NODA, TAKANORI ABE, YU KUMAZAKI, RYUTA HIRAI, MITSUNOBU IGARI, SATOSHI SAITO, YASUHIRO RYUNO, MISAKI IINO, YUGA TAKEDA, TOMOHIRO OHTA, JUN WATANABE, KEITA TSUKAHARA and SHINGO KATO
    Anticancer Research April 2024, 44 (4) 1583-1589; DOI: https://doi.org/10.21873/anticanres.16956
  • You have access
    Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma
    RYO SATO, YUTO MATSUSHITA, AYANA TAKEMURA, MOMOKO SUGIYAMA, KYOHEI WATANABE, HIROMITSU WATANABE, KEITA TAMURA, DAISUKE MOTOYAMA, MASAO NAGATA, ATSUSHI OTSUKA, HIROSHI FURUSE and HIDEAKI MIYAKE
    Anticancer Research February 2024, 44 (2) 781-786; DOI: https://doi.org/10.21873/anticanres.16869
  • You have access
    Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI)
    TOMOHIRO TAMURA, TAKESHI NUMATA, HIDETOSHI YANAI, RYOTA NAKAMURA, TOSHIHIRO SHIOZAWA, HIROKO WATANABE, SHINICHIRO OKAUCHI, NORIHIRO KIKUCHI, KUNIHIKO MIYAZAKI, SHIGEN HAYASHI, TAKAAKI YAMASHITA, KOICHI KURISHIMA, MASAHARU INAGAKI, HIROAKI SATOH, HIROICHI ISHIKAWA, TAKAYUKI KABURAGI, TAKEO ENDO, TORU SAKAMOTO and NOBUYUKI HIZAWA
    Anticancer Research October 2023, 43 (10) 4583-4591; DOI: https://doi.org/10.21873/anticanres.16652

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire